Top Markets
#1 Trillions Trillions +4,372.65%
#2 Ozapay Ozapay +38.33%
#3 Aria.AI Aria.AI +21.33%
#4 TRIA TRIA +14.00%
#5 Zano Zano +12.45%
#6 Osaka Protocol Osaka Protocol +12.26%
#7 DeXe DeXe +11.85%
#8 River Pts River Pts +11.61%
#9 pippin pippin +9.94%
#10 Janction Janction +9.42%
Coin of the day
Trillions Trillions
Settings
Language
ENGLISH
Currency
USD
Theme
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rank in Stocks #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Share Price
$0.28545656
Market Cap
$4.50M
Change (1 day)
5.97%
Change (1 year)
0.00%
Country
FR
Trade Acticor Biotech SAS (ALACT)

Category

Healthcare
Revenue for Acticor Biotech SAS (ALACT)
Revenue in Jun 2024 TTM: 0.00
According to Acticor Biotech SAS latest financial reports the company's current revenue (TTM) is 0.00. In 2022 the company made a revenue of 0.00 equal to the revenue in the year 2021 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Acticor Biotech SAS from 2010 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 $57.46K -99.46%
2017 $10.59M -27.26%
2016 $14.56M -21.24%
2015 $18.49M -22.69%
2014 $23.92M -0.83%
2013 $24.11M 21.74%
2012 $19.81M 44.80%
2011 $13.68M 52.66%
2010 $8.96M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B -
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU